VX-702

For research use only.

Catalog No.S6005

30 publications

VX-702 Chemical Structure

CAS No. 745833-23-2

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 79 In stock
USD 70 In stock
USD 110 In stock
USD 370 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's VX-702 has been cited by 30 publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
Features Highly selective, orally active inhibitor of p38 MAPK.
Targets
p38α [1]
(Cell-free assay)
4 nM-20 nM
In vitro

Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. [1] VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-62 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXfJcohq[mm2aX;uJI9nKGi3bXHuJGhQWC14MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNFE2PDNizszN M3rrXnNCVkeHUh?=
human NCI-H720 cell M2q1Vmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3S1fmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3NlAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjBzNkiyJO69VQ>? NXLhc5VPW0GQR1XS
JVM-2 cell MofWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWnadnlvUW6qaXLpeIlwdiCxZjDoeY1idiCMVl2tNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODh|IN88US=> NFTYRnJUSU6JRWK=
human NCI-H69 cell NFm3e3lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoG2TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSE[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQTl2MTFOwG0> MnLIV2FPT0WU
human BV-173 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGraTXJKdmirYnn0bY9vKG:oIHj1cYFvKEKYLUG3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTF|OE[g{txO M3rPNXNCVkeHUh?=
human KU812 cell MnjBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXTvS5RlUW6qaXLpeIlwdiCxZjDoeY1idiCNVUixNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTJ2OEig{txO NWPpVIxiW0GQR1XS
human DU-145 cell NVPQTIxGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoDJTY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE1PTV2IN88US=> MX;TRW5ITVJ?
KARPAS-45 cell MnnpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NILrclhKdmirYnn0bY9vKG:oIHj1cYFvKEuDUmDBV{01PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUS4NlYh|ryP NVzX[3ZSW0GQR1XS
human AGS cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUWyOVEh|ryP Ml:zV2FPT0WU
human MOLT-13 cell NG\yOFVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYH0coZSUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVE{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNUm4NUDPxE1? NFzBcoZUSU6JRWK=
human NCI-H209 cell MoXkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2\aS2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF5NUig{txO NV;hV3l[W0GQR1XS
human CTV-1 cell NX\ifYQ2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFr0dmZKdmirYnn0bY9vKG:oIHj1cYFvKEOWVj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yQDN6OTFOwG0> M3ryUnNCVkeHUh?=
LU-139 cell MmjvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEjNOHNKdmirYnn0bY9vKG:oIHj1cYFvKEyXLUGzPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTl2M{Wg{txO NXnwc21vW0GQR1XS
ML-2 cell NX\pcplJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{LyS2lvcGmkaYTpc44hd2ZiaIXtZY4hVUxvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlI3PjFizszN NEDuVFFUSU6JRWK=
human K5 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHzRdFlKdmirYnn0bY9vKG:oIHj1cYFvKEt3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNlkyPyEQvF2= MnrSV2FPT0WU
human SBC-1 cell M1exXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4i1fmlvcGmkaYTpc44hd2ZiaIXtZY4hW0KFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{PjJizszN MYrTRW5ITVJ?
human COR-L88 cell M2jpUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGDHb2dKdmirYnn0bY9vKG:oIHj1cYFvKEORUj3MPFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|NEig{txO NF\qc4pUSU6JRWK=
human KY821 cell NWHOXmF7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmnxTY5pcWKrdHnvckBw\iCqdX3hckBMYTh{MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|k3ODNizszN MYTTRW5ITVJ?
human HCC2218 cell NWrFcpBHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIDn[HVKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{KyNVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR7N{K4JO69VQ>? MXTTRW5ITVJ?
human ECC10 cell NGLlUpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWPOSGJpUW6qaXLpeIlwdiCxZjDoeY1idiCHQ1OxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjV|OEmg{txO MoDPV2FPT0WU
human EW-3 cell Mn\IS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGVYNTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLk[2OlEyKM7:TR?= NYLlVXhxW0GQR1XS
human EW-18 cell MlS0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFvKTXlKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUG4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44PDZ5OTFOwG0> Mn7uV2FPT0WU
human UACC-257 cell MljFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUnJcohq[mm2aX;uJI9nKGi3bXHuJHVCS0NvMkW3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zODN{NjFOwG0> MY\TRW5ITVJ?
human G-361 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHTsTIJKdmirYnn0bY9vKG:oIHj1cYFvKEdvM{[xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41QTVzOTFOwG0> MmPhV2FPT0WU
human HMV-II cell M2Pv[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXfJcohq[mm2aX;uJI9nKGi3bXHuJGhOXi2LSTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuO|cyQDRizszN NEizSndUSU6JRWK=
human DEL cell NEXMZlZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2TTZ2lvcGmkaYTpc44hd2ZiaIXtZY4hTEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6yNFcxPCEQvF2= MXnTRW5ITVJ?
human IGROV-1 cell NV;JV3ZMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF\qXXFKdmirYnn0bY9vKG:oIHj1cYFvKEmJUl;WMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjR|MUi4JO69VQ>? M2DuVXNCVkeHUh?=
human SK-OV-3 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF76fXpKdmirYnn0bY9vKG:oIHj1cYFvKFONLV;WMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjZzNkm3JO69VQ>? NWj3[5N[W0GQR1XS
human LAMA-84 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3v6NGlvcGmkaYTpc44hd2ZiaIXtZY4hVEGPQT24OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPzF{OESg{txO NH7ZOotUSU6JRWK=
human NCI-H510A cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mo[0TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEWxNGEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjl{NUK2JO69VQ>? MUnTRW5ITVJ?
human CP66-MEL cell MmrHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUDJcohq[mm2aX;uJI9nKGi3bXHuJGNRPjZvTVXMJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk46OzV3OTFOwG0> NFjkNpFUSU6JRWK=
human HAL-01 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkXoTY5pcWKrdHnvckBw\iCqdX3hckBJSUxvMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI4QTF6IN88US=> MWfTRW5ITVJ?
human RS4-11 cell  NYK5SVE{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEK2fGlKdmirYnn0bY9vKG:oIHj1cYFvKFKVND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPzB3N{Og{txO NIDEZWpUSU6JRWK=
human RPMI-8226 cell NFPR[FFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGTJNmVKdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtPFIzPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwOEKzO|Yh|ryP MnfDV2FPT0WU
human NCI-H82 cell NX7OTGtbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4\DbGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDl|MEWg{txO NYfYeZZzW0GQR1XS
human NY cells M3LacWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXvJcohq[mm2aX;uJI9nKGi3bXHuJG5[KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5{N{[zO{DPxE1? NYjUc2xiW0GQR1XS
human MDA-MB-361 cell MkjQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUDaU|Z6UW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND60N|E2QCEQvF2= MkLNV2FPT0WU
human MOLT-4 cell M4LEZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHP6SnJKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTlzOUOg{txO MlXYV2FPT0WU
human DU-4475 cell M{i3XWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYnvclBuUW6qaXLpeIlwdiCxZjDoeY1idiCGVT20OFc2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5yNUW2OUDPxE1? MUDTRW5ITVJ?
human ESS-1 cell M4m3Zmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn36TY5pcWKrdHnvckBw\iCqdX3hckBGW1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuNlkyPzlizszN M1HlWnNCVkeHUh?=
human NCI-H1299 cell NGLxV21Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXOxU|dtUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFEzQTliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkWzNFM{KM7:TR?= MVnTRW5ITVJ?
human COLO-684 cell NVqx[JFmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUO3O3NsUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVY5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNUixOlUh|ryP Mo\QV2FPT0WU
human MV-4-11 cell MoHVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkfKTY5pcWKrdHnvckBw\iCqdX3hckBOXi12LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44OTF7OTFOwG0> NFHwPY5USU6JRWK=
human D-542MG cell M2TTO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEi0SGtKdmirYnn0bY9vKG:oIHj1cYFvKERvNUSyUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjN7MkeyJO69VQ>? NXHxZ5FRW0GQR1XS
human A4-Fuk cell NETjfFBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVvHNYp3UW6qaXLpeIlwdiCxZjDoeY1idiCDND3GeYsh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjR|Nk[yJO69VQ>? MlPiV2FPT0WU
human HL-60 cell MnXXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX3hSZZFUW6qaXLpeIlwdiCxZjDoeY1idiCKTD22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPTJ{MUKg{txO NUP3WHRQW0GQR1XS
human NCI-H526 cell NWjUPFZ[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M37hdGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NlYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjV7OECxJO69VQ>? NEXB[3dUSU6JRWK=
human L-363 cell NWjobpM4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWTobndIUW6qaXLpeIlwdiCxZjDoeY1idiCOLUO2N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPzl{NUKg{txO NEDvXZdUSU6JRWK=
human A388 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXPROZlGUW6qaXLpeIlwdiCxZjDoeY1idiCDM{i4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45ODN6NDFOwG0> MYHTRW5ITVJ?
human MS-1 NIT2N5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4rhcWlvcGmkaYTpc44hd2ZiaIXtZY4hVVNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuPFM1PjVizszN M4S5TnNCVkeHUh?=
human JAR cell Mo\1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGrZO5pKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuPFQ6OjNizszN NXPZZ|I6W0GQR1XS
human TI-73 cell M2C0Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYfJcohq[mm2aX;uJI9nKGi3bXHuJHRKNTd|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OD6wOlIzKM7:TR?= M1OyWnNCVkeHUh?=
human CTB-1 cell MlPZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4LYS2lvcGmkaYTpc44hd2ZiaIXtZY4hS1SELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlE4QDJ3IN88US=> M13iUHNCVkeHUh?=
human SK-NEP-1 cell NFzvSW5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3O1XGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTlXQMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOS5|MEO4JO69VQ>? MonIV2FPT0WU
human HT-29 cell M{DKfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn3tTY5pcWKrdHnvckBw\iCqdX3hckBJXC1{OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGzMlkyOTFizszN NHfafmJUSU6JRWK=
human NCI-H1092 cell M{PPVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4GyZWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNFkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTRwM{G4JO69VQ>? NEC1Z3BUSU6JRWK=
human KMOE-2 cell NXnuZ4JFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGrNOItKdmirYnn0bY9vKG:oIHj1cYFvKEuPT1WtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjZzN{ig{txO NIPMOmpUSU6JRWK=
human EM-2 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MojQTY5pcWKrdHnvckBw\iCqdX3hckBGVS1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUWuNlg1OSEQvF2= MU\TRW5ITVJ?
human RT-112 cell MofVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoO5TY5pcWKrdHnvckBw\iCqdX3hckBTXC1zMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU4{QTh2IN88US=> NFzNb2pUSU6JRWK=
human DB cell NV;5dXVVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGfqbVVKdmirYnn0bY9vKG:oIHj1cYFvKESEIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUWuPFUyOyEQvF2= MYnTRW5ITVJ?
human NCI-H1770 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{KzTmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO|cxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[Xl? MmTzV2FPT0WU
human CAL-54 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG2Mlc{KM7:TR?= NEOxbGRUSU6JRWK=
human NB14 cell NWfCSVlyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFrMNnFKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xO{43Ozl3IN88US=> MWfTRW5ITVJ?
human RPMI-7951 cell M{P6ZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4DUZ2lvcGmkaYTpc44hd2ZiaIXtZY4hWlCPST23PVUyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTlwMUe4N{DPxE1? MV3TRW5ITVJ?
human T47D cell NVX6foxZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUjJcohq[mm2aX;uJI9nKGi3bXHuJHQ1P0RiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{MT6yNlQ{KM7:TR?= M37qcXNCVkeHUh?=
human A549 cell M3f2S2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M37J[WlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKxMlI5OTFizszN NFS0W4lUSU6JRWK=
human A2780 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHzmcZhKdmirYnn0bY9vKG:oIHj1cYFvKEF{N{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvQDJ{NTFOwG0> Ml30V2FPT0WU
human SK-MEL-24 cell NYPyc45ST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFr0SldKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0zPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTN|LkCzNVEh|ryP MVnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally. [2] VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score. [3] VX-702 selectively inhibits activation of p38 MAPK after ischemia with no effects on ERKs and JNKs. The MI/AAR ratio is significantly reduced in the 50 mg/kg group compared with the 5 mg/kg and vehicle groups.[4]

Protocol

Solubility (25°C)

In vitro DMSO 81 mg/mL (200.34 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O
For best results, use promptly after mixing.
4 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 404.3
Formula

C19H12F4N4O2

CAS No. 745833-23-2
Storage powder
in solvent
Synonyms N/A
Smiles C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00395577 Completed Drug: VX-702 Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy VX-702 | VX-702 supplier | purchase VX-702 | VX-702 cost | VX-702 manufacturer | order VX-702 | VX-702 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID